These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38769016)

  • 1. Development and Verification of a Full Physiologically Based Pharmacokinetic Model for Sublingual Buprenorphine in Healthy Adult Volunteers that Accounts for Nonlinear Bioavailability.
    van Hoogdalem MW; Tanaka R; Johnson TN; Vinks AA; Mizuno T
    Drug Metab Dispos; 2024 Jul; 52(8):785-796. PubMed ID: 38769016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically-Based Pharmacokinetic Modeling to Investigate the Effect of Maturation on Buprenorphine Pharmacokinetics in Newborns with Neonatal Opioid Withdrawal Syndrome.
    van Hoogdalem MW; Johnson TN; McPhail BT; Kamatkar S; Wexelblatt SL; Ward LP; Christians U; Akinbi HT; Vinks AA; Mizuno T
    Clin Pharmacol Ther; 2022 Feb; 111(2):496-508. PubMed ID: 34679189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration.
    Kalluri HV; Zhang H; Caritis SN; Venkataramanan R
    Br J Clin Pharmacol; 2017 Nov; 83(11):2458-2473. PubMed ID: 28688108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder.
    Dong R; Wang H; Li D; Lang L; Gray F; Liu Y; Laffont CM; Young M; Jiang J; Liu Z; Learned SM
    Drugs R D; 2019 Sep; 19(3):255-265. PubMed ID: 31197606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Forecasting Fetal Buprenorphine Exposure through Maternal-Fetal Physiologically Based Pharmacokinetic Modeling.
    van Hoogdalem MW; Tanaka R; Abduljalil K; Johnson TN; Wexelblatt SL; Akinbi HT; Vinks AA; Mizuno T
    Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Drug-Drug Interaction Liability for Buprenorphine Extended-Release Monthly Injection Administered by Subcutaneous Route.
    Kharidia J; Howgate EM; Laffont CM; Liu Y; Young MA
    Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1064-1074. PubMed ID: 33750027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability of sublingual buprenorphine.
    Mendelson J; Upton RA; Everhart ET; Jacob P; Jones RT
    J Clin Pharmacol; 1997 Jan; 37(1):31-7. PubMed ID: 9048270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers.
    Jönsson M; Mundin G; Sumner M
    Eur J Pharm Sci; 2018 Sep; 122():125-133. PubMed ID: 29940217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality.
    Harris DS; Mendelson JE; Lin ET; Upton RA; Jones RT
    Clin Pharmacokinet; 2004; 43(5):329-40. PubMed ID: 15080765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine.
    Lim SCB; Schug S; Krishnarajah J
    Pain Med; 2019 Jan; 20(1):143-152. PubMed ID: 29309700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gestational changes in buprenorphine exposure: A physiologically-based pharmacokinetic analysis.
    Zhang H; Kalluri HV; Bastian JR; Chen H; Alshabi A; Caritis SN; Venkataramanan R
    Br J Clin Pharmacol; 2018 Sep; 84(9):2075-2087. PubMed ID: 29873094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations.
    Nath RP; Upton RA; Everhart ET; Cheung P; Shwonek P; Jones RT; Mendelson JE
    J Clin Pharmacol; 1999 Jun; 39(6):619-23. PubMed ID: 10354966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial.
    Gunderson EW; Hjelmström P; Sumner M;
    Clin Ther; 2015 Oct; 37(10):2244-55. PubMed ID: 26412801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study.
    Albayaty M; Linden M; Olsson H; Johnsson M; Strandgården K; Tiberg F
    Adv Ther; 2017 Feb; 34(2):560-575. PubMed ID: 28070862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salivary Therapeutic Monitoring of Buprenorphine in Neonates After Maternal Sublingual Dosing Guided by Physiologically Based Pharmacokinetic Modeling.
    Alsmadi MM
    Ther Drug Monit; 2024 Aug; 46(4):512-521. PubMed ID: 38366333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naïve healthy male volunteers under a naltrexone block.
    McAleer SD; Mills RJ; Polack T; Hussain T; Rolan PE; Gibbs AD; Mullins FG; Hussein Z
    Drug Alcohol Depend; 2003 Oct; 72(1):75-83. PubMed ID: 14563545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome.
    Ng CM; Dombrowsky E; Lin H; Erlich ME; Moody DE; Barrett JS; Kraft WK
    Pharmacotherapy; 2015 Jul; 35(7):670-80. PubMed ID: 26172282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers.
    Bai SA; Xiang Q; Finn A
    Clin Ther; 2016 Feb; 38(2):358-69. PubMed ID: 26804639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetic Modeling After Repeated Administrations of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Use Disorder.
    Laffont CM; Gomeni R; Heidbreder C; Jones JP; Nasser AF
    J Clin Pharmacol; 2016 Jul; 56(7):806-15. PubMed ID: 26479717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study.
    Parikh N; Goskonda V; Chavan A; Dillaha L
    Clin Ther; 2013 Mar; 35(3):236-43. PubMed ID: 23497761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.